The patent cliff continues to pressure pharmaceutical stocks, as numerous high-profile drugs face a wave of patent expiration. Pfizer's Lipitor -- formerly the world's best-selling drug -- is under pressure from cheap generics but has managed to hold on to its blockbuster status. In its recent quarterly results Lipitor is still pulling its weight, racking up $545 million in sales, making it Pfizer's fifth-best selling drug.
In this segment from The Motley Fool's health care show Market Checkup, analysts David Williamson and Max Macaluso discuss how Pfizer is managing to decrease the steepness of Lipitor's patent cliff, which generic company is benefiting with Pfizer's blessing, and how a Supreme Court ruling may hurt future big pharma tactics.
Follow David on Twitter: @MotleyDavid.
